...
首页> 外文期刊>Scientific reports. >Clinical usefulness of C-reactive protein to albumin ratio in predicting 30-day mortality in critically ill patients: A retrospective analysis
【24h】

Clinical usefulness of C-reactive protein to albumin ratio in predicting 30-day mortality in critically ill patients: A retrospective analysis

机译:C反应蛋白与白蛋白比在预测危重患者30天死亡率中的临床效用:回顾性分析

获取原文
           

摘要

This study aimed to examine the prognostic value of C-reactive protein (CRP)/albumin (ALB) ratio among patients who were admitted to the intensive care unit (ICU) in predicting 30-day mortality rate. This retrospective cohort study was conducted by examining the medical records of adult patients who were admitted to the ICU at Seoul National University Bundang Hospital between 1 January 2012 and 31 December 2016. Data from 6,972 individuals were included in the final analysis, and 547 of these individuals (7.1%) died within 30 days after their ICU admission. The multivariable Cox regression analysis revealed that an increase of 1 for the CRP/ALB ratio was associated with an 11% increase in the risk of 30-day mortality (hazard ratio: 1.11, 95% confidence interval: 1.09–1.14, P??0.001). However, the area under curve of CRP/ALB ratio in receiver operating characteristic analysis was lower than that of Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II, Charlson comorbidity index, or serum albumin alone. Although an elevated CRP/ALB ratio on ICU admission was an independent risk factor for 30-day mortality rate, the predictive power of CRP/ALB ratio was lower than that of albumin alone, APACHE II, and Charlson comorbidity index.
机译:本研究旨在检查重症监护病房(ICU)入院患者中C反应蛋白(CRP)/白蛋白(ALB)比率对预测30天死亡率的预后价值。这项回顾性队列研究是通过研究2012年1月1日至2016年12月31日在首尔国立大学盆唐医院入住ICU的成年患者的医疗记录进行的。最终分析中包括了6,972人的数据,其中有547人(7.1%)个人在接受ICU后30天内死亡。多变量Cox回归分析显示,CRP / ALB比增加1会使30天死亡风险增加11%(危险比:1.11,95%置信区间:1.09-1.14,P < 0.001)。然而,接受者工作特征分析中的CRP / ALB比曲线下面积低于急性生理学评估和慢性健康评估(APACHE)II,查尔森合并症指数或仅血清白蛋白。尽管ICU入院时CRP / ALB比升高是30天死亡率的独立危险因素,但CRP / ALB比的预测能力低于单独使用白蛋白,APACHE II和Charlson合并症指数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号